Mycosynthetix owns a unique collection of fungi that are the source of a rich variety of fungal metabolites for lead discovery for medicine and agriculture.

Archive | News

RSS feed for this section

NIH Funding to Boston University, UNCG, Mycosynthetix, and others for nanoparticle-based innovative therapy to treat drug resistant cancer

Boston University’s Mark Grinstaff has been awarded a new National Institute of Health/National Cancer Institute (NIH/NCI) R01 grant. The funding will be used in collaboration with University of North Carolina Greensboro (UNCG), Augusta University, Brigham and Women’s Hospital (BWH) and Mycosynthetix. The five year grant is to study the development of a combination therapy that […]

Read full story

Mycosynthetix in Brazil for Thinking Big About Small Beings: Recent Advances On Microbial Diversity, Ecology and Biodiscovery

Mycosynthetix presented at Thinking Big About Small Beings: Recent Advances On Microbial Diversity, Ecology and Biodiscovery in São Paulo, Brazil on April 28-29. The presentation was titled Searching for Anti-Cancer and Anti-Parasite Leads from Filamentous Fungi. Abstract: Fungi have been the source of numerous successful medicines and pesticides although it isn’t obvious why fungi make […]

Read full story

Recent Natural Products Presentations by Mycosynthetix

Mycosynthetix CEO Dr. Cedric Pearce has given presentations on natural products in Japan and Canada recently. In Japan he spoke at the Mycological Society of Japan Meeting at the Tokyo University of Agriculture and the Microbial Workshop at Tamagawa University. In Canada he presented at the Weed Science Society of America/Canadian Weed Science Society Joint […]

Read full story

Mycosynthetix Discusses Fungi on Radio In Vivo

Mycosynthetix CEO Dr. Cedric Pearce was featured on the May 8, 2013 edition of Radio In Vivo, a weekly broadcast that features in-depth interviews with the researchers who make the Research Triangle of North Carolina one of the world’s leading hubs of scientific research and development.  In the interview, Dr. Pearce discusses the origins of Mycosythetix, […]

Read full story

New Website Launched

Mycosynthetix is pleased to present our new website.  If you encounter any problems using our website, please don’t hesitate to let us know.

Read full story

Mycosynthetix Celebrates 10 Years

We are pleased to celebrate 10 years of Mycosynthetix.  We look forward to further developing the potential for world-changing natural products from the fungal kingdom in the coming decade.

Read full story

Mycosynthetix Awarded 2 Therapeutic Discovery Project Grants

Mycosynthetix, Inc has been awarded two Therapeutic Discovery Project Grants by the IRS. The grants are for projects that “showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness.”

Read full story

Antimalarial Constituents of Microorganisms

Mycosynthetix CEO, Dr. Cedric Pearce, and colleagues presented at the 51st Annual Meeting of the American Society of Pharmacognosy in Tampa, Florida this July. Their presentation focused on the antimalarial compounds which have been discovered within microorganisms, such as the fungi in the Mycosynthetix library.

Read full story

Mevalocidin – novel natural herbicide under development

Mycosynthetix is currently developing Mevalocidin, a new herbicidal natural product from fungal fermentation, for use in organic farming. The US Patent for Mevalocidin (PDF) was issued on July 1st, 2008. Dow AgroSciences LLC of Indianapolis and Mycosynthetix Inc have entered into a royalty-bearing agreement for Mycosynthetix to develop and market this herbicide. Contact Dr. Cedric […]

Read full story